BioStock: Aptahem on the comparative study between Apta-1 and dexamethasone

For half a century Dexamethasone has been used to treat diseases such as rheumatoid arthritis and asthma. Four years ago, Malmö-based Aptahem was able to present preclinical data that indicate that Apta-1 in some important aspects is better than dexamethasone in hyper inflammatory conditions. A British study recently found that dexamethasone significantly reduces the risk of death from Covid-19. BioStock reached out to the company’s CSO Luiza Jedlina for a comment. 

Read the full interview with Luiza Jedlina at biostock.se:

https://www.biostock.se/en/aptahem-on-the-comparative-study-between-apta-1-and-dexamethasone/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se